Global HDAC Inhibitors Market

1. Summary

The Global HDAC Inhibitors Market was valued at $1.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 8.1% CAGR, to an estimated market size of $2.2 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The HDAC Inhibitors market comprises therapeutic agents that modulate gene expression by inhibiting histone deacetylase enzymes to restore acetylation equilibrium. These drugs are primarily utilized in oncology for treating hematologic malignancies and solid tumors, with expanding applications in neurology, autoimmune disorders, and rare diseases like Duchenne Muscular Dystrophy.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the HDAC Inhibitors Market in the period 2025-30:

• A significant shift toward developing isoform-selective inhibitors is underway to improve safety profiles and reduce the off-target toxicity associated with pan-HDAC inhibitors.
• The exploration of combination therapies pairing HDAC inhibitors with immune checkpoint inhibitors or chemotherapy is enhancing clinical efficacy in resistant tumors.
• Market expansion is being driven by the utility of these agents in non-oncology indications, particularly for neurodegenerative and fibrotic disorders.
• The development of oral formulations is a key trend aimed at increasing patient accessibility and compliance compared to traditional parenteral administration.
• Integration of precision medicine and companion diagnostics is allowing for better patient stratification based on specific epigenetic mutations.
• The rising global prevalence of hematological malignancies, such as T-cell lymphoma and multiple myeloma, remains the primary driver for core market growth.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: